ClinicalTrials.gg
RecruitingNCT05632757FARPUpdated Oct 29, 2026

Anticipated Patient and Caregiver Burden

An interventional study of Psychological assessments in Amyotrophic Lateral Sclerosis, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Amyotrophic Lateral Sclerosis with a site in France — 28 open to participants now, 36 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · France.

Planned enrollment
38th of 103
126 · median 83
Started
2023
with 10 others
No phase
47 of 132
14 open now
Primary completion
2026-12
later than 12 of 35 live
Registered
102nd of 132
by date
Lead sponsor
7 of 132
Assistance Publique Hopitaux De Marseille

Among the 132 studies in Amyotrophic Lateral Sclerosis with a site in France, this one is the 38th largest by planned enrollment of the 103 interventional ones that give a count, is one of 11 that started in 2023, is one of 47 with no phase, reaches primary completion later than 12 of the 35 other live ones, and was the 102nd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

28 of the 132 studies in Amyotrophic Lateral Sclerosis with a site in France are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Amyotrophic Lateral Sclerosis with a site in France, or all of them as a file.
02

Study summary

Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years. The severity of the disease, the progressive loss of autonomy that leads to dependence on family and caregivers, and the lack of effective treatment sometimes leads patients to a loss of hope and to dark thoughts. The prevalence of suicidal ideation is high, with more than one third of people with ALS experiencing it. The psychological suffering of patients is often associated with that of their caregivers. The evaluation of the patients' feeling of being a burden has rarely been addressed in previous studies in ALS on the notion of burden. In this work, the investigators wish to evaluate the patient's ideas of death by also taking into account the caregiver's burden and the patient's feeling of being a burden. They wish to better understand this difficult experience by refocusing the study on the patient himself, which has rarely been addressed in studies on ALS and the notion of burden. By working on the caregiver's burden, both from the caregiver's point of view and as perceived by the patient, the investigators hope to find avenues of intervention and define actions that could help patients and their families and improve the quality of life of the patient-caregiver couple.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • amyotrophic lateral sclerosis
  • caregiver
  • burden
  • depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (patient) :

  • Patient is at least 18 years of age.
  • Patient having given
  • Patient with ALS who has already had at least two multidisciplinary assessments in the ALS center in Marseille with an evaluation by the clinical psychologist.
  • Patient with a motor handicap of grade 3 to 5 on the Rankin score
  • Patient with a primary family caregiver at home (spouse, child) willing to participate in the study
  • Patient who is a beneficiary of or affiliated with a social security plan

Inclusion Criteria (caregiver) :

  • Adult subject at least 18 years of age.
  • Subject who has given informed consent.
  • Primary family caregiver of a patient with ALS who agrees to participate in the study
  • Caregiver present during hospital visits.

Exclusion Criteria (patient):

  • Patients with a serious and unstable associated disease, cardiac, oncological, hepatic or renal, psychiatric (schizophrenia, bipolar)
  • Autonomous patient, who does not need the help of a third party for the basic gestures of daily life (Rankin 0 to 2)
  • Patient living in an institution or alone at home
  • Patient with cognitive impairment that interferes with activities of daily living
  • Patients with marked emotional lability (spasmodic crying) due to ALS
  • Patients who have had a recent diagnosis of their disease (less than 6 months)
  • Patients who are unaware of the severity of their condition
  • Any condition that in the opinion of the investigator or psychologist would not be compatible with the study.

Exclusion Criteria (caregiver):

  • Subjects with severe and unstable cardiac, oncological, hepatic, renal or other illnesses.
  • Subject with a history of psychiatric illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Psychological assessments

    Behavioral: Psychological assessments

Interventions

  • BehavioralPsychological assessments

    The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.

06

What researchers measure

Primary outcomes

  1. Impact of the patient's sense of being a burden on the patient's suicidal ideation

    Columbia scale (highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

Secondary outcomes

  1. Relationship between the patient's feeling of being a burden living

    Patient's Feelings of Burden Scale (highest score meaning worst outcome)

    Time frame: Inclusion visit (month 0)

  2. Relationship between the patient's reasons for living

    Patient Reasons for Living Scale (highest score meaning worst outcome)

    Time frame: Inclusion visit (month 0)

  3. Relationship between the patient's feeling of being a burden and the caregiver's feeling of hardship

    Patient's sense of burden scale and Zarit Caregiver Exertion Scale

    Time frame: Inclusion visit (month 0)

  4. Impact of the patient's sense of burden and the caregiver's sense of hardship on the quality of life of the patient and the caregiver

    WHOQOL-Bref (World Health Organization Quality of Life, highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

  5. Relationship between the patient's feeling of being a burden and the motor disability

    Beck scale (highest score meaning worse outcome)

    Time frame: Inclusion visit (month 0)

  6. Relationship between the patient's feeling of being a burden and the motor disability

    Rankin scale (highest score meaning worse outcome)

    Time frame: Inclusion visit (month 0)

  7. Relationship between the patient's feeling of being a burden and the motor disability

    ALSFRS score (highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

  8. Relationship between the depression of patient and the caregiver

    Beck scale (highest score meaning worse outcome)

    Time frame: Inclusion visit (month 0)

  9. Relationship between the depression of patient and the caregiver

    Rankin scale (highest score meaning worse outcome)

    Time frame: Inclusion visit (month 0)

  10. Relationship between the depression of patient and the caregiver

    ALSFRS score (highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

  11. Impact of the caregiver's feeling of hardship on the patient's reasons for living

    Patient Reasons for Living Scale (highest score meaning worst outcome)

    Time frame: Inclusion visit (month 0)

  12. Impact of the caregiver's feeling of hardship on the patient's reasons for living

    Columbia Scale (highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

  13. Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation

    Patient Reasons for Living Scale (highest score meaning worst outcome)

    Time frame: Inclusion visit (month 0)

  14. Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation

    Columbia Scale (highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

  15. Relationship between the caregiver's perceived distress and the patient's suicidal ideation

    Zarit scale (highest score meaning worse outcome)

    Time frame: Inclusion visit (month 0)

  16. Relationship between the caregiver's perceived distress and the patient's suicidal ideation

    Columbia Scale (highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

  17. Relationship between caregiver's perceived distress and the patient's cognitive assessment

    ECAS score (Cognitif Edinburgh Cognitive and Behavioural ALS Screen) (highest score meaning better outcome)

    Time frame: Inclusion visit (month 0)

07

Study locations

1 of 1 sites recruiting
  • Service Maladies neuromusculaires et SLA
    Marseille, 13005, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 42 months is close to that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Dec 1, 2022
StartActual
Jun 22, 2023
Primary completionEst.
Dec 22, 2026
CompletionEst.
Jun 22, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date, oversight details, site details and index terms
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 5 other changes: identifiers, verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05632757
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Jun 22, 2023
Primary completion
Dec 22, 2026 (estimated)
Completion
Jun 22, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Annie Verschueren
Contact
annie.verschueren@ap-hm.fr
0491386578 ext. 33
Annie Verschueren
Contact
Annie Verschueren
principal investigator · AP-HM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion